Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015
作者: Cécile BrouardMarjorie Boussac-ZarebskaChristine SilvainJulien DurandVictor de LédinghenJosiane PillonelElisabeth Delarocque-Astagneau
作者单位: 1Santé publique France, the national public health agency
2Hepatology Unit, University Hospital
3Haut-Lévêque Hospital, Bordeaux University Hospital
4INSERM 1181, Biostatistics, Biomathematics, Pharmacoepidemiology, and Infectious Diseases (B2PHI)
5Institut Pasteur, B2PHI
6Versailles Saint-Quentin University, UMR 1181, B2PHI
刊名: BMC Infectious Diseases, 2017, Vol.17 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s12879-017-2889-4
关键词: Hepatitis CTreatmentDirect-acting antiviralsHealth insurance dataEpidemiologyFrance
英文摘要: The last decade was marked by major advances in HCV treatment with the introduction of first wave protease inhibitors (1st-wave PIs, telaprevir or boceprevir) in 2011 and second direct-acting antivirals (2nd-wave DAAs) in 2014, that followed low effective pegylated interferon α / ribavirin bitherapy. We estimated the number of patients initiating HCV treatment in France between 2007 and 2015 according to the type of therapy, described their demographical characteristics, and estimated how many were cured with 2nd-wave DAAs in 2014–2015.
原始语种摘要: The last decade was marked by major advances in HCV treatment with the introduction of first wave protease inhibitors (1st-wave PIs, telaprevir or boceprevir) in 2011 and second direct-acting antivirals (2nd-wave DAAs) in 2014, that followed low effective pegylated interferon α / ribavirin bitherapy. We estimated the number of patients initiating HCV treatment in France between 2007 and 2015 according to the type of therapy, described their demographical characteristics, and estimated how many were cured with 2nd-wave DAAs in 2014–2015.
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:3.025 (2012)

×
关键词翻译
关键词翻译
  • treatment 处理
  • advances 预付款
  • France 法国法郎
  • introduction 导言
  • effective 有效的
  • insurance 保险
  • estimated 估计的
  • ribavirin 三氮唑核苷
  • acting 动作
  • interferon 干扰素